Close
Novotech
Jabsco PureFlo 21 Single Use

Berkshire Sterile to offer formulation, lyophilization, and method development services

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Drug Manufacturing Deals Shift to Europe Despite Tariffs

Biopharma companies are continuing to redirect production strategies toward...

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...

How Lead Selection Impacts CMC Strategy in Drug Development

The molecule you choose to advance into development doesn't just define your science it defines your entire Chemistry, Manufacturing, and Controls roadmap. This article unpacks how early lead selection decisions ripple through CMC planning, regulatory timelines, and ultimately, your path to the clinic.
- Advertisement -

Berkshire Sterile Manufacturing (BSM), a sterile filling contract manufacturer located in Lee, MA, has recently added formulation, lyophilization, and method development capabilities to complement their clients’ drug productions.

BSM will now offer first-in-human formulation development, supply material for preclinical studies, and conduct research-level stability studies. BSM will also offer formulation optimization, process development, process optimization, and scale up studies. They will perform formulation development using materials and equipment representative of future GMP manufacturing. This information is shared with BSM’s quality control group to allow them a head start in their analytical method feasibility, evaluation, and development.

For clients looking to enhance their drug product stability through freeze-drying, BSM can develop their lyophilization formulation, lyo cycles based on thermal properties, and scale-up the lyo process when the client moves on in their clinical trials or to commercialization. BSM offers the unique ability to handle the development through commercialization to finalize their clients’ processes for a successful commercial presentation.

These new service offerings will reduce timelines, lower risk for technology transfers, and provide high-level expertise for scale-up and cGMP activities.

BSM has also expanded their capabilities in the lab to include method development. BSM will design methods to obtain the desired analytical measurements with the appropriate characteristics. During method development the accuracy, precision, linearity, and specificity will be assessed as well as system suitability requirements. The BSM team will provide a development report detailing the laboratory work that was performed and expectations for performance of the method. In addition, a draft test method will also be provided.

Following method development, BSM can perform method qualification or validation, as appropriate for the development phase of the product.

About Berkshire Sterile Manufacturing

Berkshire Sterile is a state-of-the-art fill/finish contract manufacturer which specializes in sterile filling of syringes, vials and cartridges for the biotech and pharmaceutical industries. BSM also offers terminal steam sterilization of syringes, specialty filling, lyophilization of vials, dual chamber liquid/liquid and liquid/lyo all within an isolator. Analytical services, stability studies, lyophilization development, formulation development, and method development are also offered.

Latest stories

Related stories

Drug Manufacturing Deals Shift to Europe Despite Tariffs

Biopharma companies are continuing to redirect production strategies toward...

DeepCyte Raises $1.5M funding to Advance AI Drug Toxicology

DeepCyte, a techbio company focused on advancing AI Drug...

How Lead Selection Impacts CMC Strategy in Drug Development

The molecule you choose to advance into development doesn't just define your science it defines your entire Chemistry, Manufacturing, and Controls roadmap. This article unpacks how early lead selection decisions ripple through CMC planning, regulatory timelines, and ultimately, your path to the clinic.

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »